Inflammation

Items 71-80 of 210

per page
Set Descending Direction
  1. HpARI (CCP1/2) (rec.) (His)
    AG-40B-0201
    AG-40B-0201-C05050 µg
    CHF 440.00
    AG-40B-0201-30503 x 50 µg
    CHF 880.00
    HpARI (CCP1/2) (rec.) (His)
  2. IDO1 (mouse) (rec.) (His)
    AG-40A-0030
    AG-40A-0030-C05050 µg
    CHF 515.00
  3. IGFL (mouse) (rec.)
    AG-40B-0091
    AG-40B-0091-C01010 µg
    CHF 420.00
  4. IGFL1 (human) (rec .)
    AG-40B-0244
    AG-40B-0244-C01010 µg
    CHF 380.00
    AG-40B-0244-30103 x 10 µg
    CHF 760.00
    IGFL1 (human) (rec .)
  5. IGFL3 (human) (rec.)
    AG-40B-0090
    AG-40B-0090-C01010 µg
    CHF 420.00
    AG-40B-0090-30103 x 10 µg
    CHF 840.00
    IGFL3 (human) (Prod. No. AG-40B-0090) binds to its receptor IGFLR1 (human):Fc (human) (Prod. No. AG-40B-0087). Method: IGFLR1 (human):Fc was coated on an ELISA plate at 1μg/ml overnight at room temperature. IGFL-3 (human) or a negative control, Ome
  6. IGFL4 (human) (rec.) (His)
    AG-40B-0251
    AG-40B-0251-C01010 µg
    CHF 380.00
    AG-40B-0251-30103 x 10 µg
    CHF 760.00
    IGFL4 (human) (rec.) (His)
  7. IGFLR1 (human):Fc (human) (rec.)
    AG-40B-0087
    AG-40B-0087-C05050 µg
    CHF 470.00
    IGFLR1 (human):Fc (human) (Prod. No. AG-40B-0087) binds to its ligand IGFL-3 (human) (Prod. No. AG-40B-0090). Method: IGFLR1 (human):Fc was coated on an ELISA plate at 1μg/ml overnight at room temperature. IGFL-3 (human) or a negative control
  8. IL-1β (human) (rec.) (untagged)
    AG-40B-0023
    AG-40B-0023-C01010 µg
    CHF 215.00
    AG-40B-0023-30103 x 10 µg
    CHF 430.00
    IL-1β (human) (rec.) (untagged)
  9. IL-1β (mouse) (rec.) (untagged)
    AG-40B-0086
    AG-40B-0086-C01010 µg
    CHF 260.00
    AG-40B-0086-30103 x 10 µg
    CHF 505.00
  10. IL-12 (mouse):Fc (LALA-PG)-KIH (human) (rec.)
    AG-40B-0255
    AG-40B-0255-C05050 µg
    CHF 440.00
    NEW IL-12 (mouse):Fc (LALA-PG)-KIH (human) (rec.)

Items 71-80 of 210

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.